Predict your next investment

Syngulon company logo
HEALTHCARE | Biotechnology
syngulon.com

See what CB Insights has to offer

About Syngulon

Syngulon develops original genetic technologies to improve the efficiency of microorganisms.

Syngulon Headquarter Location

Rue du Bois Saint Jean 15/1

Seraing, 4102,

Belgium

Latest Syngulon News

Enzymicals and Syngulon sign a non-exclusive license agreement on the use of Syngulon’s antibiotic free technology to produce enzymes

May 17, 2020

Enzymicals and Syngulon sign a non-exclusive license agreement on the use of Syngulon’s antibiotic free technology to produce enzymes May 17, 2020 Enzymicals AG, a German enterprise focusing on industrial biocatalysis and Syngulon, a Belgian synthetic biology company developing original genetic technologies using bacteriocins, announce a non-exclusive license agreement which provides Enzymicals access to Syngulon’s patented selection technology. SERAING, BELGIUM (PRWEB) MAY 16, 2020 Enzymicals AG, a German enterprise focusing on industrial biocatalysis and Syngulon, a Belgian synthetic biology company developing original genetic technologies using bacteriocins, announce a non-exclusive license agreement which provides Enzymicals access to Syngulon’s patented selection technology. Syngulon’s technology expands the capacity for selection of microorganisms. Synthetic biology uses the concept of “bioengineering” to improve or modify existing genetic systems to create microbes with desired behaviors, and Syngulon uses this approach to develop its selection technology (US patent 9,333,227/10,188,114). It is based on bacteriocins, ribosomally-produced peptides naturally made by most bacteria to kill competitive microbial species. This technology offers advantageous over antibiotic selection for several reasons: it avoids the use of antibiotics in the first place, helping to reduce the spread of antibiotic resistant microbes. The technology also increases product yield; as bacteriocins are generally smaller peptides, they do not impose a heavy metabolic burden on the producing cell. They can have a wide target specificity, helping to avoid genetic drift. Finally, the system is 100% plasmid-based (e.g. without chromosomal mutations), making it applicable for use in any E. coli strains. Enzymicals offers a broad selection of recombinant enzymes suitable for research, development, production and diagnostics as well as a tailor-made protein expression and optimization service. There is a growing interest for antibiotic-free production of enzymes coming from customers and the technology is currently applied in a first project for the production of diagnostic enzymes for a world leader that requires antibiotic-free production. Dr. Ulf Menyes, CEO of Enzymicals AG, states “This genetic technology will make our microbial strains involved in industrial processes safer and more efficient. We are happy to now use this innovation in our own applications as well as for specific developments for our clients.” Guy Hélin, CEO of Syngulon, added “This is the second license agreement that we announce on our technologies and we are very happy to work with Enzymicals on their project for a world leader in diagnostic enzymes”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Syngulon Patents

Syngulon has filed 6 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Chemical processes
  • Lactobacillaceae
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/31/2016

1/29/2019

Molecular biology, Microbiology, Yeasts, Chemical processes, Lactobacillaceae

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/31/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/29/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Microbiology, Yeasts, Chemical processes, Lactobacillaceae

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.